Guardant Health (GH) and Quest Diagnostics (DGX) announced a strategic collaboration to make Guardant’s Shield blood-based screening test available to physicians and patients served by Quest in the United States. Shield is expected to be available for physician order through Quest in the first quarter of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health: Buy Rating Backed by Growth Potential and Innovation in Cancer Screening
- Craig-Hallum healthcare/pharma analysts hold analyst/industry conference call
- Humana initiated, Paycom upgraded: Wall Street’s top analyst calls
- Guardant Health initiated with an Overweight at Wells Fargo
- Guardant Health Expands Board, Appoints Alex Azar